<DOC>
	<DOCNO>NCT02125500</DOCNO>
	<brief_summary>Aim study ass efficacy safety 24 week oral Sofosbuvir/Ledipasvir fixed-dose combination ( FDC ) subject HCV genotype 1 infection HIV co-infection , previously fail NS3/4A protease inhibitor plus Pegylated interferon /ribavirin regimen stop prematurely treatment intolerance .</brief_summary>
	<brief_title>Pilot Study Assess Efficacy Safety Sofosbuvir/Ledipasvir Fixed-dose Combination Treatment Experienced Subjects With Hepatitis C Virus ( HCV ) Genotype 1 - HIV Co-infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Confirmed HIV infection Infection HCV genotype 1 , confirm screen visit , HCVRNA ≥ 1000 InternationalUnit ( IU ) /mL screen visit Treatmentexperienced subject : previous virological failure tritherapy Peginterferon/Ribavirin protease inhibitor , premature discontinuation previous tritherapy Peginterferon/Ribavirin protease inhibitor due intolerance Peginterferon protease inhibitor AntiHCV treatment stop least last 3 month Patients stable ( 1 month ) antiretroviral treatment consist emtricitabine/tenofovir lamivudine/tenofovir standard care backbone plus efavirenz raltegravir rilpivirine enfuvirtide . Alternative combination list medication may allow . Dendritic cell 4 &gt; 100/mm3 &gt; 15 % screen visit HIVRNA &lt; 50cp/ml 3 month screen visit Any liver fibrosis grade , assessment presence cirrhosis screening , cirrhosis define METAVIR score F4 liver puncture biopsy and/or hepatic impulse elastometry ≥ 15 kilopascal ( kPa ) : Previous liver biopsy exhibit cirrhosis lesion ( METAVIR F4 ) , and/or significant liver biopsy ( cumulative length ≥ 15mm ≥ 6 portal space ) , within past 18 month and/or significant reliable liver stiffness assessment ( Fibroscan® ) within past 6 month ( least 10 measure IQR le 25 % mean value success rate least 80 % ) . Female patient childbearing potential , heterosexual partner must use adequate contraception date screen 90 day administration last dose study drug . Male participant must agree consistently correctly use condom , female partner must use adequate contraception date screen 90 day administration last dose study drug Body weight ≥40 kg ≤125 kg Informed sign consent main study Pharmacokinetic ( PK ) substudy ( participate patient ) Patients Health insurance Non inclusion Criteria : ChildPugh B C cirrhosis history decompensated cirrhosis . Coinfection Hepatitis B virus ( HBV ) ( AgHBs + ) HBV DNA &gt; 1000 UI/ml Pregnant breastfeed woman Transplant recipient Opportunistic infection ( stage C ) , active occur within 6 month prior baseline Evolutive malignancy , include hepatocarcinoma control prior baseline Alcohol drug consumption may affect study participation accord investigator . Patients include programme substitution methadone buprenorphine could enrol . The opinion consultant addictology recommend patient present current drug use drug use previous year . Patients history nonadherence , risk unable respect study followup timetable Patients participate another clinical trial within 30 day prior inclusion Hb &lt; 10 g/dL ( female ) &lt; 11g/dL ( male ) Platelets &lt; 50 000/mm3 Neutrophil count &lt; 750/mm3 Renal failure define creatinin clearance ( MDRD ) &lt; 60ml/min Other antiretroviral drug allow study Contraindications Sofosbuvir , Ledipasvir Contraindicated treatment likely interfere study drug list protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HCV/HIV coinfection</keyword>
	<keyword>HCV genotype 1</keyword>
</DOC>